HomeRGEN • NASDAQ
Repligen Corp
Follow
$111.94
8.02%
Pre-market:(7.09%)-7.94
$104.00
Closed: Apr 7, 6:20:00 AM GMT-4 · USD · NASDAQ · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 167.55M | 0.56% |
Operating expense | 72.00M | 6.82% |
Net income | -33.87M | -105.89% |
Net profit margin | -20.21 | -104.76% |
Earnings per share | 0.44 | 33.33% |
EBITDA | 26.68M | -25.93% |
Effective tax rate | 12.27% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 757.36M | 0.80% |
Total assets | 2.83B | -0.05% |
Total liabilities | 856.95M | -1.08% |
Total equity | 1.97B | — |
Shares outstanding | 56.15M | — |
Price to book | 3.46 | — |
Return on assets | 0.73% | — |
Return on capital | 0.78% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -33.87M | -105.89% |
Cash from operations | 39.18M | 34.79% |
Cash from investing | -64.76M | 61.88% |
Cash from financing | 1.45M | -99.46% |
Net change in cash | -26.61M | -122.07% |
Free cash flow | 78.77M | 152.48% |
Previous close
$121.70
Day range
$106.78 - $118.42
Year range
$106.78 - $182.21
Market cap
6.28B USD
Avg Volume
735.25K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Repligen Corporation is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. In February 2014, Repligen had employed 116 people, about 50% of these based in Sweden. Wikipedia
CEO
Founded
1981
Headquarters
Website
Employees
1,778
